©The Author(s) 2026.
World J Clin Oncol. Feb 24, 2026; 17(2): 116251
Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.116251
Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.116251
Table 1 Baseline characteristics stratified by cancer stem cell phenotype, n (%)
| Characteristic | CSC-negative (n = 230) | CSC-positive (n = 26) | P value |
| Age, mean (SD) | 46.8 (9.4) | 45.3 (10.4) | 0.457 |
| Menopausal status | 0.116 | ||
| Pre | 117 (50.9) | 18 (69.2) | |
| Post | 113 (49.1) | 8 (30.8) | |
| Tumor grade | 0.198 | ||
| 1 | 33 (14.3) | 6 (23.1) | |
| 2 | 67 (29.1) | 10 (38.5) | |
| 3 | 130 (56.5) | 10 (38.5) | |
| Stage | 0.666 | ||
| I | 68 (29.6) | 8 (30.8) | |
| II | 72 (31.3) | 10 (38.5) | |
| III | 90 (39.1) | 8 (30.8) | |
| Ki-67, mean (SD) | 42.7 (13.4) | 38.0 (11.7) | 0.088 |
| Chemotherapy type | 0.708 | ||
| Neoadjuvant | 164 (71.3) | 20 (76.9) | |
| Adjuvant | 66 (28.7) | 6 (23.1) | |
| Surgery | 0.847 | ||
| Mastectomy | 141 (61.3) | 17 (65.4) | |
| Breast-conserving | 89 (38.7) | 9 (34.6) | |
| Radiation | 189 (82.2) | 21 (80.8) | 1.000 |
- Citation: Depar FN, Chaudhary AJ, Hameed J, Abbasi FS, Uzma B, Ali A, Akhtar N, Khan R, Siddiqi A, Riaz S. Cancer stem cell markers, chemotherapy response, and survival in triple-negative breast cancer. World J Clin Oncol 2026; 17(2): 116251
- URL: https://www.wjgnet.com/2218-4333/full/v17/i2/116251.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i2.116251